JP7072508B2 - 変異型ｐ５３と関連している疾患、障害または病状の処置におけるペプチドおよびその使用 - Google Patents

変異型ｐ５３と関連している疾患、障害または病状の処置におけるペプチドおよびその使用 Download PDF

Info

Publication number
JP7072508B2
JP7072508B2 JP2018540383A JP2018540383A JP7072508B2 JP 7072508 B2 JP7072508 B2 JP 7072508B2 JP 2018540383 A JP2018540383 A JP 2018540383A JP 2018540383 A JP2018540383 A JP 2018540383A JP 7072508 B2 JP7072508 B2 JP 7072508B2
Authority
JP
Japan
Prior art keywords
peptide
dbd
amino acid
cancer
pcap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018540383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512004A (ja
JP2019512004A5 (enExample
Inventor
ヴァルダ ロッター，
モシェ オーレン，
ペリー タル，
シェイ アイゼンベルガー，
アヴィ ベン－シモン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of JP2019512004A publication Critical patent/JP2019512004A/ja
Publication of JP2019512004A5 publication Critical patent/JP2019512004A5/ja
Priority to JP2022077818A priority Critical patent/JP2022112518A/ja
Application granted granted Critical
Publication of JP7072508B2 publication Critical patent/JP7072508B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018540383A 2016-02-04 2017-02-03 変異型ｐ５３と関連している疾患、障害または病状の処置におけるペプチドおよびその使用 Active JP7072508B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022077818A JP2022112518A (ja) 2016-02-04 2022-05-10 変異型ｐ５３と関連している疾患、障害または病状の処置におけるペプチドおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291003P 2016-02-04 2016-02-04
US62/291,003 2016-02-04
PCT/IL2017/050132 WO2017134671A1 (en) 2016-02-04 2017-02-03 Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022077818A Division JP2022112518A (ja) 2016-02-04 2022-05-10 変異型ｐ５３と関連している疾患、障害または病状の処置におけるペプチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2019512004A JP2019512004A (ja) 2019-05-09
JP2019512004A5 JP2019512004A5 (enExample) 2020-03-19
JP7072508B2 true JP7072508B2 (ja) 2022-05-20

Family

ID=58108701

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018540383A Active JP7072508B2 (ja) 2016-02-04 2017-02-03 変異型ｐ５３と関連している疾患、障害または病状の処置におけるペプチドおよびその使用
JP2022077818A Pending JP2022112518A (ja) 2016-02-04 2022-05-10 変異型ｐ５３と関連している疾患、障害または病状の処置におけるペプチドおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022077818A Pending JP2022112518A (ja) 2016-02-04 2022-05-10 変異型ｐ５３と関連している疾患、障害または病状の処置におけるペプチドおよびその使用

Country Status (8)

Country Link
US (1) US11230578B2 (enExample)
EP (1) EP3411390A1 (enExample)
JP (2) JP7072508B2 (enExample)
CN (1) CN108884137B (enExample)
AU (1) AU2017214733B2 (enExample)
CA (1) CA3012302A1 (enExample)
RU (1) RU2762089C2 (enExample)
WO (1) WO2017134671A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016002721A2 (pt) 2013-08-07 2018-07-10 Yeda Research And Development Company Ltd. peptídeos capazes de reativar p53 mutantes
US20220251159A1 (en) * 2016-02-04 2022-08-11 Yeda Research And Development Co., Ltd Peptides and use of same in the treatment of diseases, disroders or conditions associated with a mutant p53
CA3012302A1 (en) 2016-02-04 2017-08-10 Yeda Research And Development Co. Ltd. Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
EP4121441A1 (en) * 2020-03-16 2023-01-25 Yeda Research and Development Co. Ltd Peptide analogs and use of same in treating diseases, disorders or conditions associated with a mutant p53 protein
CN112578106B (zh) * 2020-04-13 2022-04-22 南京大学 一种纳米孔道单分子蛋白质测序仪
CN112921032A (zh) * 2020-12-29 2021-06-08 苏州中科先进技术研究院有限公司 一种引物对、探针、试剂盒及其使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013036208A1 (en) 2011-09-09 2013-03-14 Agency For Science, Technology And Research P53 activating peptides
WO2015019318A1 (en) 2013-08-07 2015-02-12 Yeda Research And Development Co. Ltd. Peptides capable of reactivating p53 mutants

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5294605A (en) * 1990-07-19 1994-03-15 The Scripps Research Institute Amphiphilic peptide compositions and analogues thereof
US5614393A (en) 1991-10-10 1997-03-25 Rhone-Poulenc Agrochimie Production of γ-linolenic acid by a Δ6-desaturase
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5969120A (en) 1993-09-03 1999-10-19 Research Development Foundation Mutants of the RB and P53 genes
US6184205B1 (en) 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
US5711376A (en) 1995-12-07 1998-01-27 Marathon Oil Company Hydraulic fracturing process
US5877282A (en) * 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
AU7238098A (en) 1997-05-15 1998-12-08 Kyowa Hakko Kogyo Co. Ltd. Peptides having cyclic structures and exerting p53 protein activty-restoring effect on p53 protein mutants
HUP0201215A2 (en) * 1998-12-02 2002-08-28 Pfizer Prod Inc Methods and compositions for restoring conformational stability of a protein of the p53 family
US20030224379A1 (en) 2000-01-21 2003-12-04 Tang Y. Tom Novel nucleic acids and polypeptides
BR0207068A (pt) 2001-01-26 2004-12-21 Inhibitex Inc Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus
WO2002068601A2 (en) 2001-02-28 2002-09-06 Skubitz Keith M Small peptides capable of modulating the function of cd66 (ceacam) family members
US20070128657A1 (en) 2002-01-23 2007-06-07 El-Gewely Mohamed R Molecular libraries
US7361747B2 (en) 2003-05-22 2008-04-22 The University Of Hong Kong Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus
RU2007138027A (ru) 2005-03-14 2009-04-20 Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем (Us) Биоактивные пептиды fus-1 и комплексы полипептидов с наночастицами
GB0514538D0 (en) * 2005-07-14 2005-08-24 Ludwig Inst Cancer Res Variant polypeptide and screening assay
WO2009112075A1 (en) 2008-03-13 2009-09-17 Universita' Degli Studi Di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function
US8287845B2 (en) 2008-12-18 2012-10-16 E I Du Pont De Nemours And Company Hair-binding peptides
CN101805738B (zh) * 2009-11-12 2012-03-21 昆明理工大学 早老综合征所致ALT肿瘤的特有p53突变蛋白-p53N236S及其应用
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
CA3012302A1 (en) 2016-02-04 2017-08-10 Yeda Research And Development Co. Ltd. Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013036208A1 (en) 2011-09-09 2013-03-14 Agency For Science, Technology And Research P53 activating peptides
WO2015019318A1 (en) 2013-08-07 2015-02-12 Yeda Research And Development Co. Ltd. Peptides capable of reactivating p53 mutants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cell Cycle，2009年01月01日，Vol.8, No.1，pp.137-148

Also Published As

Publication number Publication date
CN108884137B (zh) 2022-04-05
US11230578B2 (en) 2022-01-25
RU2018131120A (ru) 2020-03-05
CN108884137A (zh) 2018-11-23
AU2017214733B2 (en) 2022-09-29
WO2017134671A1 (en) 2017-08-10
JP2022112518A (ja) 2022-08-02
US20190048053A1 (en) 2019-02-14
EP3411390A1 (en) 2018-12-12
CA3012302A1 (en) 2017-08-10
JP2019512004A (ja) 2019-05-09
AU2017214733A1 (en) 2018-09-06
RU2762089C2 (ru) 2021-12-15
RU2018131120A3 (enExample) 2020-06-25

Similar Documents

Publication Publication Date Title
JP7072508B2 (ja) 変異型ｐ５３と関連している疾患、障害または病状の処置におけるペプチドおよびその使用
CA2650113C (en) Compositions for treatment of cancer
ES2795982T3 (es) Péptidos capaces de reactivar mutantes de p53
Sudo et al. Human-derived fusogenic peptides for the intracellular delivery of proteins
WO2012137036A1 (en) Cell penetrating peptides for intracellular delivery of molecules
Mokhtarieh et al. Novel cell penetrating peptides with multiple motifs composed of RGD and its analogs
JP2022502347A (ja) 細胞透過性ペプチド
JP5700409B2 (ja) Ｈｓｐ９０を標的にした新規抗がんキメラペプチド
CN115397513A (zh) 改进的抗衰老化合物及其用途
KR20230136910A (ko) Brk 펩티드 및 사용 방법
JP2005514348A (ja) 腫瘍リンパ性脈管構造を目指すペプチドおよびその使用方法
US10316077B2 (en) Cell-penetrating ATF5 polypeptides and uses thereof
WO2011152662A2 (ko) Ptd-uqcrb 융합 폴리펩타이드 및 그를 포함하는 허혈성 질환의 예방 및 치료용 약제학적 조성물
JP2019510015A (ja) Ｂｃｌ−２ ｌ１０／ｉｐ３受容体の相互作用の阻害剤
US20220251159A1 (en) Peptides and use of same in the treatment of diseases, disroders or conditions associated with a mutant p53
Eissa Enhancing the delivery of therapeutic cargo to cancer cells using cell penetrating peptides
HK1219742B (en) Peptides capable of reactivating p53 mutants

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220510

R150 Certificate of patent or registration of utility model

Ref document number: 7072508

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150